(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are ESSA Pharma, Aspen Group, and Corvus Pharmaceuticals.

The three biggest losers today are Wayfair, Foresight Autonomous Holdings Ltd., and DiaMedica Therapeutics.

Winners today

1. ESSA Pharma (EPIX) – 11.11%

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

NASDAQ ended the session with ESSA Pharma jumping 11.11% to $3.00 on Thursday while NASDAQ slid 0.82% to $13,679.04.

Earnings Per Share

As for profitability, ESSA Pharma has a trailing twelve months EPS of $-0.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.28%.

Yearly Top and Bottom Value

ESSA Pharma’s stock is valued at $3.00 at 17:32 EST, way under its 52-week high of $5.16 and way higher than its 52-week low of $1.40.

Volume

Today’s last reported volume for ESSA Pharma is 133507 which is 166.05% above its average volume of 50180.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ESSA Pharma’s EBITDA is 4.53.

More news about ESSA Pharma.

2. Aspen Group (ASPU) – 7.86%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group jumping 7.86% to $0.14 on Thursday while NASDAQ slid 0.82% to $13,679.04.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Sales Growth

Aspen Group’s sales growth is negative 24% for the ongoing quarter and negative 29.3% for the next.

Volume

Today’s last reported volume for Aspen Group is 33100 which is 55.15% below its average volume of 73808.

Moving Average

Aspen Group’s value is way above its 50-day moving average of $0.11 and way below its 200-day moving average of $0.28.

Volatility

Aspen Group’s last week, last month’s, and last quarter’s current intraday variation average was a negative 9.79%, a negative 2.29%, and a positive 7.11%.

Aspen Group’s highest amplitude of average volatility was 9.79% (last week), 4.67% (last month), and 7.11% (last quarter).

More news about Aspen Group.

3. Corvus Pharmaceuticals (CRVS) – 7.56%

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

NASDAQ ended the session with Corvus Pharmaceuticals jumping 7.56% to $2.42 on Thursday, following the last session’s upward trend. NASDAQ dropped 0.82% to $13,679.04, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Corvus Pharmaceuticals has a trailing twelve months EPS of $-0.88.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59%.

Moving Average

Corvus Pharmaceuticals’s value is higher than its 50-day moving average of $2.34 and way above its 200-day moving average of $1.22.

Yearly Top and Bottom Value

Corvus Pharmaceuticals’s stock is valued at $2.42 at 17:32 EST, way below its 52-week high of $4.19 and way higher than its 52-week low of $0.61.

More news about Corvus Pharmaceuticals.

4. Eiger BioPharmaceuticals (EIGR) – 7.09%

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

NASDAQ ended the session with Eiger BioPharmaceuticals jumping 7.09% to $0.78 on Thursday, after three consecutive sessions in a row of gains. NASDAQ dropped 0.82% to $13,679.04, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Eiger BioPharmaceuticals has a trailing twelve months EPS of $-2.06.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -146.28%.

Volume

Today’s last reported volume for Eiger BioPharmaceuticals is 1031860 which is 102.2% above its average volume of 510306.

More news about Eiger BioPharmaceuticals.

5. DermTech (DMTK) – 6.27%

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

NASDAQ ended the session with DermTech rising 6.27% to $3.05 on Thursday while NASDAQ slid 0.82% to $13,679.04.

Earnings Per Share

As for profitability, DermTech has a trailing twelve months EPS of $-3.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -75.85%.

Yearly Top and Bottom Value

DermTech’s stock is valued at $3.05 at 17:32 EST, way below its 52-week high of $8.93 and way above its 52-week low of $1.55.

Earnings Before Interest, Taxes, Depreciation, and Amortization

DermTech’s EBITDA is -1.38.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 3% and 8.3%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.5%, now sitting on 14.28M for the twelve trailing months.

More news about DermTech.

6. Cardiff Oncology (CRDF) – 5.8%

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

NASDAQ ended the session with Cardiff Oncology jumping 5.8% to $1.46 on Thursday while NASDAQ slid 0.82% to $13,679.04.

Earnings Per Share

As for profitability, Cardiff Oncology has a trailing twelve months EPS of $-0.84.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.36%.

Moving Average

Cardiff Oncology’s value is way below its 50-day moving average of $1.64 and under its 200-day moving average of $1.59.

Yearly Top and Bottom Value

Cardiff Oncology’s stock is valued at $1.46 at 17:32 EST, way below its 52-week high of $3.41 and way higher than its 52-week low of $1.20.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12.2%, now sitting on 395k for the twelve trailing months.

Volatility

Cardiff Oncology’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.36%, a negative 0.97%, and a positive 3.28%.

Cardiff Oncology’s highest amplitude of average volatility was 6.16% (last week), 2.85% (last month), and 3.28% (last quarter).

More news about Cardiff Oncology.

7. Enochian Biosciences (ENOB) – 5.28%

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

NASDAQ ended the session with Enochian Biosciences jumping 5.28% to $0.53 on Thursday while NASDAQ fell 0.82% to $13,679.04.

Earnings Per Share

As for profitability, Enochian Biosciences has a trailing twelve months EPS of $-2.44.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -93.88%.

Moving Average

Enochian Biosciences’s worth is way under its 50-day moving average of $0.88 and way under its 200-day moving average of $1.29.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Enochian Biosciences’s EBITDA is -13.87.

Yearly Top and Bottom Value

Enochian Biosciences’s stock is valued at $0.53 at 17:32 EST, way below its 52-week high of $2.99 and way higher than its 52-week low of $0.39.

More news about Enochian Biosciences.

8. Kodak (KODK) – 4.82%

Eastman Kodak Company provides hardware, software, consumables, and services to customers in the commercial print, packaging, publishing, manufacturing, and entertainment markets worldwide. The company operates through four segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment offers digital offset plate and computer-to-plate imaging solutions to commercial industries, including commercial print, direct mail, book publishing, newspapers and magazines, and packaging. The Digital Printing segment provides electrophotographic printing solutions, such as The ASCEND and NEXFINITY printers; prosper products, including the PROSPER 6000 Press, PROSPER Writing Systems, PROSPER press systems, and PROSPER components; versamark products; and PRINERGY workflow production software. The Advanced Materials and Chemicals segment engages in industrial film and chemicals, motion picture, and advanced materials and functional printing businesses. This segment also comprises the Kodak Research Laboratories, which conducts research, develops new product or new business opportunities, and files patent applications for its inventions and innovations, as well as manages licensing of its intellectual property to third parties. The Brand segment engages in the licensing of Kodak brand to third parties. The company engages in the operation of Eastman Business Park, a technology center and industrial complex. It sells its products and services through direct sales, third party resellers, dealers, channel partners, and distributors. Eastman Kodak Company was founded in 1880 and is headquartered in Rochester, New York.

NYSE ended the session with Kodak jumping 4.82% to $5.00 on Thursday while NYSE fell 1.22% to $15,641.67.

Earnings Per Share

As for profitability, Kodak has a trailing twelve months EPS of $0.53.

PE Ratio

Kodak has a trailing twelve months price to earnings ratio of 9.43. Meaning, the purchaser of the share is investing $9.43 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.5%.

More news about Kodak.

9. 89bio (ETNB) – 3.92%

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

NASDAQ ended the session with 89bio rising 3.92% to $19.09 on Thursday, following the last session’s upward trend. NASDAQ fell 0.82% to $13,679.04, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, 89bio has a trailing twelve months EPS of $-2.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.39%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

89bio’s EBITDA is -33.07.

Yearly Top and Bottom Value

89bio’s stock is valued at $19.09 at 17:32 EST, way under its 52-week high of $22.93 and way higher than its 52-week low of $3.15.

More news about 89bio.

10. Teva Pharmaceutical (TEVA) – 3.4%

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

NYSE ended the session with Teva Pharmaceutical rising 3.4% to $7.74 on Thursday, after two consecutive sessions in a row of gains. NYSE fell 1.22% to $15,641.67, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Teva Pharmaceutical has a trailing twelve months EPS of $-1.44.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.93%.

More news about Teva Pharmaceutical.

Losers Today

1. Wayfair (W) – -10.98%

Wayfair Inc. engages in the e-commerce business in the United States and internationally. The company provides approximately fourty million products for the home sector under various brands. It offers online selections of furniture, décor, housewares, and home improvement products through its sites, including Wayfair, Joss & Main, AllModern, Birch Lane, Perigold, and Wayfair Professional. The company was founded in 2002 and is headquartered in Boston, Massachusetts.

NYSE ended the session with Wayfair falling 10.98% to $56.84 on Thursday, after two consecutive sessions in a row of losses. NYSE fell 1.22% to $15,641.67, following the last session’s downward trend on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, Wayfair has a trailing twelve months EPS of $-12.99.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 61.3% and 63.5%, respectively.

Moving Average

Wayfair’s worth is way higher than its 50-day moving average of $43.77 and way above its 200-day moving average of $40.42.

Yearly Top and Bottom Value

Wayfair’s stock is valued at $56.84 at 17:32 EST, way below its 52-week high of $76.35 and way above its 52-week low of $28.11.

Sales Growth

Wayfair’s sales growth is negative 6.3% for the ongoing quarter and 1.1% for the next.

More news about Wayfair.

2. Foresight Autonomous Holdings Ltd. (FRSX) – -10.91%

Foresight Autonomous Holdings Ltd., a technology company, engages in the design, development, and commercialization of sensor systems for the automotive industry in Israel and China. It develops in-line-of-sight vision systems and beyond-line-of-site cellular-based applications. The company offers QuadSight system, a quad-camera multi-spectral vision system for the semi-autonomous and autonomous vehicle market; V2X (vehicle-to-everything), an accident prevention solution based on real-time multi-agents positioning algorithms that enables communication between vehicles, infrastructure, grid, home, and network; and Eye-Net Protect, a cellular-based V2X solution that provides real-time pre-collision alerts to vulnerable road users, such as pedestrians, cyclists, scooter drivers, etc. by using smartphones. It has a strategic cooperation agreement with FLIR Systems, Inc. to develop, market, and distribute QuadSight vision system. The company was formerly known as Asia Development (A.D.B.M.) Ltd. and changed its name to Foresight Autonomous Holdings Ltd. in 2016. Foresight Autonomous Holdings Ltd. was incorporated in 1977 and is headquartered in Ness Ziona, Israel.

NASDAQ ended the session with Foresight Autonomous Holdings Ltd. sliding 10.91% to $2.45 on Thursday while NASDAQ fell 0.82% to $13,679.04.

Earnings Per Share

As for profitability, Foresight Autonomous Holdings Ltd. has a trailing twelve months EPS of $-3.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -67.66%.

Yearly Top and Bottom Value

Foresight Autonomous Holdings Ltd.’s stock is valued at $2.45 at 17:32 EST, way below its 52-week high of $5.88 and way above its 52-week low of $1.75.

Volume

Today’s last reported volume for Foresight Autonomous Holdings Ltd. is 94981 which is 47.5% above its average volume of 64391.

Moving Average

Foresight Autonomous Holdings Ltd.’s value is way higher than its 50-day moving average of $2.17 and way under its 200-day moving average of $2.99.

More news about Foresight Autonomous Holdings Ltd..

3. DiaMedica Therapeutics (DMAC) – -10.45%

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

NASDAQ ended the session with DiaMedica Therapeutics falling 10.45% to $3.94 on Thursday, following the last session’s downward trend. NASDAQ dropped 0.82% to $13,679.04, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, DiaMedica Therapeutics has a trailing twelve months EPS of $-0.59.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.55%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 38.5% and a negative 8.3%, respectively.

Volume

Today’s last reported volume for DiaMedica Therapeutics is 319138 which is 153.44% above its average volume of 125920.

More news about DiaMedica Therapeutics.

4. Tattooed Chef (TTCF) – -9.85%

Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, wood fire crusted pizza, handheld burritos, and bars and quesadillas. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores, as well as online. Tattooed Chef, Inc. is headquartered in Paramount, California.

NASDAQ ended the session with Tattooed Chef falling 9.85% to $0.26 on Thursday, after four consecutive sessions in a row of losses. NASDAQ slid 0.82% to $13,679.04, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Tattooed Chef has a trailing twelve months EPS of $-0.9.

More news about Tattooed Chef.

5. Evelo Biosciences (EVLO) – -9.63%

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Evelo Biosciences sliding 9.63% to $2.91 on Thursday while NASDAQ slid 0.82% to $13,679.04.

Earnings Per Share

As for profitability, Evelo Biosciences has a trailing twelve months EPS of $-0.93.

Moving Average

Evelo Biosciences’s value is above its 50-day moving average of $2.80 and way below its 200-day moving average of $20.41.

Yearly Top and Bottom Value

Evelo Biosciences’s stock is valued at $2.91 at 17:32 EST, way below its 52-week high of $65.80 and way above its 52-week low of $0.48.

More news about Evelo Biosciences.

6. Crexendo (CXDO) – -9.34%

Crexendo, Inc. provides cloud communication platform and services, video collaboration, and managed IT services for businesses in the United States, Canada, and internationally. It operates through two segments, Cloud Telecommunications and Software Solutions. The Cloud Telecommunications segment provides telecommunications services that transmit calls using Internet protocol (IP) or cloud technology, which converts voice signals into digital data packets for transmission over the Internet or cloud; and broadband Internet services. This segment is also involved in the sale and lease of cloud telecommunications equipment. In addition, it offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over high-speed internet connection through various devices and user interfaces, such as desktop phones and/or mobile, and desktop applications under the Crexendo brand name. The Software Solutions segment provides suite of unified communications, video conferencing, collaboration, and contact center solutions. This segment also offers SNAPsolution, a IP-based platform; and SNAPaccel, a software-as-a-service based software, as well as provides subscription maintenance and support, and professional services, including consulting, technical support, resident engineer, design, and installation services. The company was formerly known as iMergent, Inc. and changed its name to Crexendo, Inc. in May 2011. Crexendo, Inc. was incorporated in 1995 and is based in Tempe, Arizona.

NASDAQ ended the session with Crexendo dropping 9.34% to $1.65 on Thursday, following the last session’s downward trend. NASDAQ fell 0.82% to $13,679.04, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Crexendo has a trailing twelve months EPS of $-1.52.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -67.06%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 50% and a negative 33.3%, respectively.

Moving Average

Crexendo’s worth is above its 50-day moving average of $1.64 and way below its 200-day moving average of $1.92.

More news about Crexendo.

7. SmileDirectClub (SDC) – -8.89%

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

NASDAQ ended the session with SmileDirectClub sliding 8.89% to $0.50 on Thursday, after five consecutive sessions in a row of gains. NASDAQ dropped 0.82% to $13,679.04, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.628.

More news about SmileDirectClub.

8. Ebix (EBIX) – -8.06%

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

NASDAQ ended the session with Ebix falling 8.06% to $23.60 on Thursday while NASDAQ slid 0.82% to $13,679.04.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $1.63.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 14.48. Meaning, the purchaser of the share is investing $14.48 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.31%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 15.2%, now sitting on 1.01B for the twelve trailing months.

More news about Ebix.

9. DIRTT Environmental Solutions Ltd. (DRTT) – -7.27%

DIRTT Environmental Solutions Ltd. designs, manufactures, and installs prefabricated interior solutions for use primarily in commercial spaces across various industries and businesses in the United States, Canada, internationally. Its ICE software interior construction technology provides integration and management, from design through engineering, manufacturing, and installation. The company's interior construction solutions include prefabricated, customized interior modular walls, ceilings, and floors; decorative and functional millwork; power infrastructure; network infrastructure; and pre-installed medical gas piping systems. It offers interior construction solutions through a network of independent distribution partners. It serves commercial, healthcare, education, hospitality, and other industries, as well as medical gas piping systems for healthcare. DIRTT Environmental Solutions Ltd. was incorporated in 2003 and is headquartered in Calgary, Canada.

NASDAQ ended the session with DIRTT Environmental Solutions Ltd. falling 7.27% to $0.25 on Thursday while NASDAQ fell 0.82% to $13,679.04.

Earnings Per Share

As for profitability, DIRTT Environmental Solutions Ltd. has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -161.52%.

Yearly Top and Bottom Value

DIRTT Environmental Solutions Ltd.’s stock is valued at $0.25 at 17:32 EST, way under its 52-week high of $1.35 and way above its 52-week low of $0.20.

More news about DIRTT Environmental Solutions Ltd..

10. Niu Technologies (NIU) – -7.22%

Niu Technologies designs, manufactures, and sells smart electric scooters in the People's Republic of China. The company offers RQi, NQi, MQi, SQi, UQi, and Gova series electric scooters and motorcycles; KQi series one kick-scooters; BQi series e-bikes; and Niu Aero Sports Bicycles. It also provides accessories and spare parts under the NIU brand name comprising scooter accessories, such as raincoats, gloves, knee pads, storage baskets and tail boxes, smart phone holders, backrests, and locks; lifestyle accessories, which includes T-shirts, coats, sweaters and hoodies, jeans, hats, bags, jewelry, notebook, badges, key chain, and mugs; and performance upgrade components that comprises of upgraded wheels, shock absorbers, brake calipers, and carbon fiber body panels. In addition, the company, through its NIU app, offers online repair request, DIY repairs, service station locator, theft reporting, smart check, and smart services, as well as NIU cover, which provides insurance services. Niu Technologies sells and services its products through city partners and franchised stores, distributors, and third-party e-commerce platforms and the company's online store. The company was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Niu Technologies falling 7.22% to $4.11 on Thursday, after two consecutive sessions in a row of gains. NASDAQ slid 0.82% to $13,679.04, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Niu Technologies has a trailing twelve months EPS of $-0.14.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.41%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 27.5%, now sitting on 3.01B for the twelve trailing months.

More news about Niu Technologies.

Stay up to date with our winners and losers daily report